Amneal Pharmaceuticals (AMRX) reported Q4 adjusted earnings Friday of $0.12 per diluted share, down from $0.14 a year earlier.
Four analysts polled by FactSet expected $0.15.
Revenue for the quarter ended Dec. 31 was $730.5 million compared with $617 million a year earlier.
Three analysts surveyed by FactSet expected $708.1 million.
The company said it expects 2025 adjusted EPS of $0.65 to $0.70 on revenue of $3 billion to $3.1 billion. Analysts surveyed by FactSet expect $0.71 and $2.92 billion, respectively.
Amneal shares were up 2.6% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.